The Role of Levamisole and HIV-1 Nef-p24 Fusion Protein in IL-4 Gene Expression for Evaluating Humoral Immune Response
Archives of Advances in Biosciences,
Vol. 11 No. 2 (2020),
16 May 2020
Introduction: Acquired immunodeficiency syndrome (AIDS) is one of the most common infectious diseases in the world. It is transmitted via the Human Immunodeficiency Virus (HIV-1). So, a HIV-1 vaccine should be eﬀective in the prevention of virus infection and induces immune responses. The main aim of this study was to evaluate the humoral immune induction through measuring the expression of interleukin4 (IL-4) in response to levamisole, as an adjuvant, with the HIV-1 Nef-p24 fusion protein as an immunogenic sequence.
Materials and Methods: In this study, 56 BalB/c female mice, aged 6 to 8 weeks were divided into 4 groups. There were 14 mice in each group. Prime and Booster injections were arranged in these groups receiving PBS, levamisole, Nef-p24, and Nef-p24 along with levamisole (Nef-p24/levamisole). All injections were performed peritoneally.
Results: Real-time PCR results showed that IL-4 transcripts level increased significantly (P <0.05) in boostered groups, receiving levamisole, Nef-p24, and Nef-p24/levamisole compared to primed groups. However, the results of ELISA revealed the enhancement in IL-4 expression in levamisole primed groups in comparison to Nef-p24/levamisole boostered group.
Conclusion: The results of the present study showed that the HIV-1 Nef-p24 fusion protein and levamisole could be considered as effective candidates as to increase the expression of IL-4 which may stimulate the humoral immune response.
- ELISA, HIV-1 Nef-p24 fusion protein, Immune response, IL-4, Levamisole, Real time
Faria NR, Rambaut A, Suchard MA, Baele G, Bedford T, Ward MJ, et al. The early spread and epidemic ignition of HIV-1 in human populations. science. 2014; 346 (6205); 56-61.
Teixeira D, Ishimura M.E., Apostólico JdS, Viel J.M., Passarelli V.C, Cunha-Neto E., et al. Propionibacterium acnes enhances the immunogenicity of hiVBr18 human immunodeficiency Virus-1 Vaccine. Frontiers in Immunology. 2018; 177.
El-Sadr W.M., Rabkin M, DeCock KM. Population Health or Individualized Care in the Global AIDS Response: Synergy or Conflict? AIDS (London, England). 2016; 30 (14): 2145.
Archin NM, Sung JM, Garrido C, Soriano-Sarabia N, Margolis DM. Eradicating HIV-1 infection: seeking to clear a persistent pathogen. Nature Reviews Microbiology. 2014; 12 (11): 750.
Kwarteng A, Ahuno ST, Kwakye-Nuako G. The therapeutic landscape of HIV-1 via genome editing. AIDS research and therapy. 2017; 14 (1):32.
Gurunathan S, Klinman DM, Seder RA. DNA vaccines: immunology, application, and optimization. Annual review of immunology.
; 18 (1): 927-74.
Delany I, Rappuoli R, De Gregorio E. Vaccines for the 21st century. EMBO molecular medicine. 2014; 6 (6): 708-720.
Smed-Sörensen A, Loré K. Targeting dendritic cells for improved HIV-1 vaccines. HIV Interactions with Dendritic Cells: Springer;
Nabel GJ. Designing tomorrow's vaccines. New England Journal of Medicine. 2013; 368 (6): 551-60.
Draper SJ, Angove E, Horii T, Miller LH, Srinivasan P, Theisen M, et al. Recent advances in recombinant protein-based malaria vaccines. Vaccine.2015; 33 (52): 7433-43.
Apostólico JdS, Lunardelli VAS, Coirada FC, Boscardin SB, Rosa DS. Adjuvants: classification, modus operandi, and licensing. Journal of immunology research.2016; 2016.
Foumani M, Asadpour L, Azizi Saraji A, Sharifat Salmani A, Aghasadeghi M. Adjuvants and Their Mechanisms of Action. Journal of Ardabil University of Medical Sciences. 2012; 12(3): 276-91.
Mahdavi M, Ebtekar M, Azadmanesh K, Khorramkhorshid H, Rahbarizadeh F, Yazdi M, et al. HIV-1Gag-Nef fusion peptide induces cellular and humoral immune response in a mouse model. Acta virologica. 2010; 54 (2): 131-6.
Zuniga R, Lucchetti A, Galvan P, Sanchez S, Sanchez C, Hernandez A, et al. Relative dominance of Gag p24-specific cytotoxic T lymphocytes is associated with human immunodeficiency virus control. Journal of virology. 2006; 80 (6): 3122-5.
Cazeaux N, Bennasser Y, Vidal P-L, Li Z, Paulin D, Bahraoui E. Compamiceive study of immune responses induced after immunization with plasmids encoding the HIV-1 Nef protein under the control of the CMV-IE or the muscle-specific desmin promoter. Vaccine. 2002; 20 (28): 3322-31.
Bråve A, Gudmundsdotter L, Gasteiger G, Hallermalm K, Kastenmuller W, Rollman E, et al. Immunization of mice with the nef gene from Human Immunodeficiency Virus type 1: Study of immunological memory and long-term toxicology. Infectious agents and cancer. 2007; 2(1): 14.
Šmahel M, Poláková I, Sobotková E, Vajdová E. Systemic administmiceion of CpG oligodeoxynucleotide and levamisole as adjuvants for gene-gun-delivered antitumor DNA vaccines. Clinical and Developmental Immunology.2011; 2011.
Huang M-B, James CO, Powell MD, Bond VC. Apoptotic peptides derived from HIV-1 Nef induce lymphocyte depletion in mice. Ethnicity and disease. 2008; 2.
Gavioli R, Cellini S, Castaldello A, Voltan R, Gallerani E, Gagliardoni F, et al. The Tat protein broadens T cell responses directed to the HIV-1 antigens Gag and Env: implications for the design of new vaccination stmiceegies against AIDS. Vaccine. 2008; 26 (5): 727-37.
Reynolds MR, Weiler AM, Piaskowski SM, Piatak Jr M, Robertson HT, Allison DB, et al. A trivalent recombinant Ad5 gag/pol/nef vaccine fails to protect rhesus macaques from infection or control virus replication after a limiting-dose heterologous SIV challenge. Vaccine. 2012; 30 (30): 4465-75.
Kang ZH, Bricault CA, Borducchi EN, Stephenson KE, Seaman MS, Pau M, et al. Similar epitope specificities of IgG and IgA antibodies elicited by Ad26 vector prime, Env protein boost immunizations in rhesus monkeys. Journal of Virology.2018; 18.
Wen J, Hao W, Fan Y, Du J, Du B, Qian M, et al. Co-delivery of LIGHT expression plasmid enhances humoral and cellular immune responses to HIV-1 Nef in mice. Archives of virology. 2014; 159 (7): 1663-9.
Omosa-Manyonyi G, Mpendo J, Ruzagira E, Kilembe W, Chomba E, Roman F, et al. A phase I double blind, placebo-controlled, randomized study of the safety and immunogenicity of an adjuvanted HIV-1 Gag-Pol-Nef fusion protein and adenovirus Gag-RT-Int-Nef vaccine in healthy HIV-uninfected African adults. PloS one. 2015; 10 (5): 954- 1025.
Gonzalez‐Rabade N, McGowan EG, Zhou F, McCabe MS, Bock R, Dix PJ, et al. Immunogenicity of chloroplast‐derived HIV‐1 p24 and a p24‐Nef fusion protein following subcutaneous and oral administmiceion in mice. Plant biotechnology journal.2011; 9 (6): 629-38.
Cosma A, Nagaraj R, Bühler S, Hinkula J, Busch DH, Sutter G, et al. Therapeutic vaccination with MVA-HIV-1 nef elicits Nef-specific T-helper cell responses in chronically HIV-1 infected individuals. Vaccine. 2003; 22 (1): 21-9.
Svanholm C, Löwenadler B, Wigzell H. Amplification of T‐cell and antibody responses in DNA‐based immunization with HIV‐1Nef by co‐injection with a GM‐CSF expression vector. Scandinavian journal of immunology. 1997; 46 (3): 298-303.
Tähtinen M, Strengell M, Collings A, Pitkänen J, Kjerrström A, Hakkarainen K, et al. DNA vaccination in mice using HIV-1 nef, rev and tat genes in self-replicating pBN-vector. Vaccine. 2001; 19 (15):2039-47.
Martins MA, Tully DC, Cruz MA, Power KA, de Santana MGV, Bean DJ, et al. Vaccine-induced SIV-specific CD8+ T-cell responses focused on a single Nef epitope select for escape variants shortly after infection. Journal of Virology. 2015; 1440-1445.
Sayad B, Alavian SM, Najafi F, Soltani B, Shirvani M, Janbakhsh A, et al. Effects of oral levamisole as an adjuvant to hepatitis b vaccine in HIV/AIDS patients: A randomized controlled trial. Hepatitis monthly.2012; 9(12).
Cazella LN. Influência do Levamisol na resposta imune humoral anti-rábica em bovinos. 2009.
Somi M-H, Ardalan M-R, Moghadaszadeh M, Shirmohamadi M, Piri R, Naghavi-Behzad M. Levamisole as an adjuvant to hepatitis B vaccination in patients with chronic kidney disease. J Anal Res Clin Med. 2015; 3(2): 87-93.
Morrison R, Nowak B, Carson J. The effect of levamisole as an adjuvant on the humoral immune response of Atlantic salmon (Salmo salar L.). BULLETIN-EUROPEAN ASSOCIATION OF FISH PATHOLOGISTS. 2002; 20 (3): 101-5.
- Abstract Viewed: 0 times
- PDF Downloaded: 0 times
- PDF Downloaded: 0 times
- PDF Downloaded: 0 times
- PDF Downloaded: 0 times